This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
Stocks · News reference
Rodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11
Rodman & Renshaw initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy rating and announces Price Target of $11.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating
William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating.
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q2 results. Revenue of $198.83M beat estimates, while adjusted EPS of $0.05 also beat.
Zentalis Pharmaceuticals shares are trading lower after the company announced the pricing of its $80.5 million proposed public offering of 23 million shares at $3.50 per share.